SEC Form 4 · accession 0001600132-18-000179
Bellerophon Therapeutics, Inc. · BLPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Fabian Tenenbaum
Officer — Chief Executive Officer
Period of report
Nov 20, 2018
Accepted (ET)
Nov 23, 2018 · 4:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001600132
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.91 | Nov 20, 2018 | A | 1,487,500 | A | — | Nov 20, 2028 | Common Stock | 1,487,500 | 3,676,197 | D |
Explanation of responses
- F1This option was granted on November 20, 2018. This option vests in quarterly installments over a four-years period from the date of grant.